Member Info for Krone

Hi RMM - so what are Stephen Parker's responsibilities i.r.o PR?
http://www.sareum.com/news/press-releases-and-news/2016/change-director/

Further response:
Hi
Right now we are focused on MOMENTUM enrollment and momelotinib’s potential regulatory filing, but are considering future development options for SRA-737. I don’t have specific timing at this juncture.

Thank you.

From:
Sent: Wednesday, November 18, 2020 10:41 AM
To: Media Inquiries
Subject: Re: Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference

Thank you for your reply. Can you please confirm when you will be providing an update in respect of SRA737?

Thank you.

Good morning,
Given that the recently announced renegotiation of the license agreement between Sierra and CRT Pioneer Fund LP clears the way for progressing this target, would you confirm please whether Dr Dilly will be providing an update in respect of SRA737 at the Jeffries conference.

Good morning

Thank you for your interest in Sierra Oncology. The main focus of Dr. Dilly’s Jefferies presentation will be momelotinib as we prepare for additional data analyses at ASH.
Thank you & do let us know if we can answer any additional questions.

Including one trade of $980k....

Welcome Brownboots....enjoy the ride!

We can expect notice of the AGM any day now. Presumably it will be a virtual format? Trust we'll get a proper opportunity to put realtime questions to the BoD.

Hi RMM- it’s just so frustrating that the good folk on here have to do the profile raising! I’m sure if we had a whip round we could rustle up enough to pay a professional PR person to do the job.
For example this tweet surely warrants a response from Tim et al: https://twitter.com/jebkeiper/status/1326942650315005957?s=21

Interest in Tyk2 might soon tick up – we took a look at the pipeline and currently only $BMY (+ Nimbus) and $PFE have pure Tyk2 inhibitors in clinical development, although there are a few more Tyk/Jak inhibitors. Via @evaluatevantage evaluate.com/vantage/articl…

https://www.evaluate.com/vantage/articles/analysis/spotlight/interest-tyk2-might-soon-tick

In the context of the last 18 months of radio silence from Sierra re SRA737 and given today's 8-K, is it reasonable to suppose that at least an outline of the revised plans for progressing further development of 737 will be announced before the Jeffries conference at which Dr Dilly is presenting next Wednesday? Dilly won't be able to present market sensitive info on the day, so we can expect a further update tomorrow, Monday or Tuesday.

Thanks, now clear!

It is badly worded, open to interpretation and needs clarification.

An opportunity for Dr Stephen Parker to grab Dr Stephen Dilly by the short and curlies, virtually!
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference
VANCOUVER, BC, Nov. 12, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the Jefferies Virtual London Healthcare Conference taking place November 17-19, 2020.
The presentation is scheduled for 7:20 pm GMT on Wednesday, November 18. A replay of the presentation will be available following the conference on the Investors section of Sierra's corporate website in the Events & Webcast tab.

But factually inaccurate, Sareum is not on the business of diagnostics or vaccines!
‘No silver bullet in the fight against #COVID19. Very welcome news from Pfizer but the sector sell off ignores there is still a place for potential diagnostic and vaccine providers such as #SENS #NCYT #SNG #TILS #SAR $SAR.L
tinyurl.com/y459rqkt via @proactive_UK #PFE

Been thinking about the statement ‘ Sareum aims to complete AT LEAST ONE pre-clinical trial this year’ .....at least one clearly implies that it may well be two....before the end of this year...
Before the end of this year means in practice before the 18th December at the latest....ie 6 weeks max....

If at any time during the course of the development or commercialisation of a Licensed Product, ProNAi fails to meet one or more of its obligations under Clauses 4.4 and 4.5 in relation to such Licensed Product for a period of [*] months or more, save where due to the acts or omissions of CPF, then CPF shall have the right to give written notice to ProNAi requesting detailed written justification for such failure and ProNAi shall provide such detailed written justification to CPF within thirty (30) Business Days of the date of CPF’s request. Where remedy is possible ProNAi shall use its Commercially Reasonable Efforts to take substantive steps to remedy such failure within sixty (60) Business Days of the date of CPF’s request. If ProNAi fails to provide such justification to CPF within thirty (30) days of the date of CPF’s request and/or use its Commercially Reasonable Efforts to take substantive steps to remedy such failure within sixty (60) Business Days of the date of CPF’s request, then, on notice by CPF to ProNAi, this Agreement will terminate in respect of the relevant Licensed Product. Any dispute between the Parties as to whether a diligence failure has arisen or whether ProNAi has used its Commercially Reasonable Efforts to take substantive steps to remedy a diligence failure shall be resolved by the Expert.
https://www.sec.gov/Archives/edgar/data/1290149/000119312516765907/d255357dex101.htm

https://www.bms.com/assets/bms/us/en-us/pdf/tyk2-pathway-fact-sheet.pdf

Important confirmation for @Sareumplc of TYK2 as a significant autoimmune target
https://twitter.com/sparksinsurrey/status/1323664584272760833?s=21

Amazing, already tweeted!
https://twitter.com/Sareumplc/status/1323607395260633088?s=20

Bristol Myers wins a big bet as their PhIII autoimmune drug beats a blockbuster sold to Amgen for $13B-plus.
Lets see if the Sareum PR Department can spin this just a little.
https://endpts.com/bristol-myers-wins-a-big-bet-as-their-phiii-autoimmune-drug-beats-a-blockbuster-sold-to-amgen-for-13b-plus/